Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Shigeyoshi Fuziwara, Ayako Suzuki, Kaori Inoue, Mitsuhiro Dend. Dopamine D2-like receptor agonists accelerate barrier repair and inhibit the epidermal hyperplasia induced by barrier disruption. The Journal of investigative dermatology. vol 125. issue 4. 2005-11-03. PMID:16185279. |
two families of g protein-coupled receptors of the neurotransmitter dopamine, i.e., dopamine 1-like family (d1-like receptor) and dopamine 2-like family (d2-like receptor), show dopaminergic activity in nerve cells. |
2005-11-03 |
2023-08-12 |
Not clear |
Spiridon Papapetropoulos, D C Mas. Psychotic symptoms in Parkinson's disease. From description to etiology. Journal of neurology. vol 252. issue 7. 2005-10-27. PMID:15999234. |
although the precise pathoetiologic mechanisms remain unknown, we review evidence that links ventral dopaminergic pathway dysfunction (overactivity) together with the involvement of other neurotransmitter system imbalances as likely contributors. |
2005-10-27 |
2023-08-12 |
Not clear |
Spiridon Papapetropoulos, D C Mas. Psychotic symptoms in Parkinson's disease. From description to etiology. Journal of neurology. vol 252. issue 7. 2005-10-27. PMID:15999234. |
the clinical importance of the proposed mechanism is that successful management of psychotic symptoms in pd may rely on a multitarget approach to restore neurotransmitter imbalances rather than focusing exclusively on the dopaminergic dysfunction. |
2005-10-27 |
2023-08-12 |
Not clear |
Teresa M du Bois, Chao Deng, Xu-Feng Huan. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 6. 2005-10-27. PMID:16005134. |
this review addresses the relationship between modifications in membrane phospholipid composition (mpc) and alterations in dopaminergic, serotonergic and cholinergic neurotransmitter systems in schizophrenia. |
2005-10-27 |
2023-08-12 |
rat |
S Rossi, S Singer, E Shearman, H Sershen, A Lajth. The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Neurochemical research. vol 30. issue 4. 2005-08-24. PMID:16076024. |
the effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. |
2005-08-24 |
2023-08-12 |
rat |
Abdurrahman Altindag, Medaim Yanik, Mehmet Asogl. The emergence of tics during escitalopram and sertraline treatment. International clinical psychopharmacology. vol 20. issue 3. 2005-08-02. PMID:15812270. |
we present a case of the emergence of tics associated with escitalopram and sertraline treatment, which might be due to an imbalance in the dopaminergic neurotransmitter system. |
2005-08-02 |
2023-08-12 |
Not clear |
Filip Scheperjans, Christian Grefkes, Nicola Palomero-Gallagher, Axel Schleicher, Karl Zille. Subdivisions of human parietal area 5 revealed by quantitative receptor autoradiography: a parietal region between motor, somatosensory, and cingulate cortical areas. NeuroImage. vol 25. issue 3. 2005-07-29. PMID:15808998. |
we studied the regional and laminar distributions of the binding sites of 12 different neurotransmitter receptors (glutamatergic: ampa, kainate, nmda; gabaergic: gabaa, gabab; cholinergic: muscarinic m2, nicotinic; adrenergic: alpha1, alpha2; serotoninergic: 5-ht1a, 5-ht2; dopaminergic: d1) in human postmortem brains by means of quantitative receptor autoradiography, since the structural and functional aspects of human ba 5 are widely unknown, and previous observations have demonstrated characteristic differences in receptor distribution between motor and somatosensory areas. |
2005-07-29 |
2023-08-12 |
human |
Rui D S Prediger, Daniel Fernandes, Reinaldo N Takahash. Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behavioural brain research. vol 159. issue 2. 2005-07-19. PMID:15817183. |
these cognitive deficits have been variously attributed to disrupted dopaminergic, cholinergic and adenosinergic neurotransmitter function. |
2005-07-19 |
2023-08-12 |
rat |
A J Herrera, M Tomás-Camardiel, J L Venero, J Cano, A Machad. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. Journal of neural transmission (Vienna, Austria : 1996). vol 112. issue 1. 2005-06-07. PMID:15599609. |
this single injection produced the induction of inflammatory process with the activation of microglia along with the specific degeneration of dopaminergic neurons in the sn without affecting neither other neurotransmitter systems nor other structures of the cns. |
2005-06-07 |
2023-08-12 |
Not clear |
Stephen I Deutsch, Katrice D Long, Richard B Rosse, John Mastropaolo, Judy Elle. Hypothesized deficiency of guanine-based purines may contribute to abnormalities of neurodevelopment, neuromodulation, and neurotransmission in Lesch-Nyhan syndrome. Clinical neuropharmacology. vol 28. issue 1. 2005-05-24. PMID:15711436. |
the neurologic manifestations may result, at least in part, from a mixture of neurodevelopmental (eg, a failure to "arborize" dopaminergic synaptic terminals) and neurotransmitter (eg, disruption of gaba and glutamate receptor-mediated neurotransmission) consequences. |
2005-05-24 |
2023-08-12 |
Not clear |
Regina Celia Cussa Kubrusly, Maria Cristina Caldas da Cunha, Ricardo Augusto de Melo Reis, Heline Soares, Ana Lúcia Marques Ventura, Eleonora Kurtenbach, Maria Cristina Fialho de Mello, Fernando Garcia de Mell. Expression of functional receptors and transmitter enzymes in cultured Muller cells. Brain research. vol 1038. issue 2. 2005-05-24. PMID:15757630. |
we developed a purified muller glia culture to investigate the expression of several neurotransmitter markers on these cells, such as dopaminergic, cholinergic, gabaergic and peptidergic receptors or enzymes, based on functional assays measuring second messenger levels or western blot for specific proteins. |
2005-05-24 |
2023-08-12 |
chicken |
Gwyneth Zai, Paul Arnold, Eliza Burroughs, Cathy L Barr, Margaret A Richter, James L Kenned. Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 134B. issue 1. 2005-05-09. PMID:15685626. |
although historically genetic testing has focused on the serotonergic and dopaminergic systems, there is increasing evidence that the major inhibitory neurotransmitter, gamma-aminobutyric acid (gaba), may also be functionally involved. |
2005-05-09 |
2023-08-12 |
Not clear |
Jolanta Rabe-Jabłońska, Adam Mille. [Links between pain and depression]. Psychiatria polska. vol 39. issue 1. 2005-04-21. PMID:15771150. |
presently we know at least five kinds of links between depression and pain: 1) depression appeared prior to the start of pain, 2) depression is a consequence of chronic pain and stress, 3) depressive episodes cause an increase of risk of next affective episodes in patients with chronic pain, 4) psychologic factors play an important role in the development of depressive symptoms, 5) altered balance between noradrenergic and serotonergic pathways and disregulation of other neurotransmitter systems (cholinergic, gaba-ergic, dopaminergic) and neuropeptides may cause chronic pain and depressive disorder. |
2005-04-21 |
2023-08-12 |
Not clear |
Mehmet Sofuoglu, Thomas R Koste. Novel approaches to the treatment of cocaine addiction. CNS drugs. vol 19. issue 1. 2005-03-21. PMID:15651902. |
gaba is the main inhibitory neurotransmitter in the brain, and accumulating evidence suggests that the gaba system modulates the dopaminergic system and cocaine effects. |
2005-03-21 |
2023-08-12 |
Not clear |
Robert B Raffa, Andrea F Martle. Amphetamine-induced increase in planarian locomotor activity and block by UV light. Brain research. vol 1031. issue 1. 2005-03-18. PMID:15621023. |
these findings strengthen the hypothesis that the effects of dopaminergic ligands and uv light on plmv relate to interaction with neurotransmitter transduction process(es). |
2005-03-18 |
2023-08-12 |
Not clear |
Giuseppe Fanciulli, Alessandra Dettori, Maria P Demontis, Paolo A Tomasi, Vittorio Anania, Giuseppe Delital. Gluten exorphin B5 stimulates prolactin secretion through opioid receptors located outside the blood-brain barrier. Life sciences. vol 76. issue 15. 2005-03-10. PMID:15698850. |
since opioid peptides do not exert their effect on prl secretion directly, but via a reduced dopaminergic tone, our data suggest that ge-b5 can modify brain neurotransmitter release without crossing the bbb. |
2005-03-10 |
2023-08-12 |
rat |
E Catalani, C Gangitano, L Bosco, G Casin. Expression of the neurokinin 1 receptor in the mouse retina. Neuroscience. vol 128. issue 3. 2005-03-04. PMID:15381281. |
different subsets of nk1 receptor-expressing amacrine cells were identified on the basis of the expression of selected neurotransmitter substances: i) about 23% of nk1 receptor-expressing amacrine cells also contained glycine; ii) the remaining 77% were likely to be gabaergic, although some inconsistency was observed in the gaba immunostaining obtained with two different gaba antibodies; iii) all dopaminergic amacrine cells also expressed nk1 receptors; iv) about one third of sp-containing amacrine cells also expressed nk1 receptors. |
2005-03-04 |
2023-08-12 |
mouse |
Waguih William Ishak, Mark H Rapaport, Jennifer G Gott. The effectiveness of atypical antipsychotic medications in depressive disorders. Current psychiatry reports. vol 6. issue 6. 2005-03-02. PMID:15538989. |
animal models suggest that when atypical antipsychotic medications are used in combination with a selective serotonin reuptake inhibitor there is additional activation of frontal dopaminergic and noradrenergic neurotransmitter systems. |
2005-03-02 |
2023-08-12 |
Not clear |
B Aouizerate, C Martin-Guehl, J Tigno. [Neurobiology and pharmacotherapy of social phobia]. L'Encephale. vol 30. issue 4. 2005-03-01. PMID:15538306. |
several lines of evidence suggest specific neurotransmitter system alterations in social phobia, especially with regard to the serotoninergic, noradrenergic and dopaminergic systems. |
2005-03-01 |
2023-08-12 |
human |
Ilonka A T M Meerts, Hellmuth Lilienthal, Saske Hoving, Johannes H J van den Berg, Bert M Weijers, Ake Bergman, Jan H Koeman, Abraham Brouwe. Developmental exposure to 4-hydroxy-2,3,3',4',5-pentachlorobiphenyl (4-OH-CB107): long-term effects on brain development, behavior, and brain stem auditory evoked potentials in rats. Toxicological sciences : an official journal of the Society of Toxicology. vol 82. issue 1. 2005-02-22. PMID:15310863. |
measurements of neurotransmitter levels revealed effects of aroclor 154 exposure on both the dopaminergic and the serotonergic systems, whereas 4-oh-cb107 exposure affected dopaminergic and noradrenergic systems, with slight but not significant effects on the serotonergic system. |
2005-02-22 |
2023-08-12 |
rat |